B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

GPR32

MOLECULAR TARGET

G protein-coupled receptor 32

UniProt: O75388NCBI Gene: 285427 compounds

GPR32 (G protein-coupled receptor 32) is targeted by 27 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting GPR32

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1Dehydroepiandrosterone0.691
2Fluoxetine0.691
3amlexanox0.691
4Aripiprazole0.691
5Astemizole Antihistamine drug now withdrawn from0.691
6Chlorhexidine0.691
7Ciclopirox0.691
8clofilium tosylate0.691
9Dehydroepiandrosterone0.691
10Deslanoside Deacetyllanatoside C.0.691
11Disulfiram0.691
12Doxazosin0.691
13lonidamine0.691
14Lynestrenol0.691
15Vitamin K 30.691
16Mestranol0.691
17Metergoline0.691
18Methimazole0.691
19Niflumic Acid0.691
20Norethindrone0.691
21Ouabain0.691
22Oxymetholone0.691
23Oxyphenbutazone0.691
24Polidocanol0.691
25Promethazine0.691
26Quinestrol0.691
27Salmeterol Xinafoate0.691

About GPR32 as a Drug Target

GPR32 (G protein-coupled receptor 32) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 27 compounds with documented GPR32 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

GPR32 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.